Can Mortality Data Provide Reliable Indicators for Creutzfeldt-Jakob Disease Surveillance? A Study in France from 2000 to 2008Brandel J.-P.a–e · Welaratne A.a · Salomon D.f, g · Capek I.h · Vaillant V.h · Aouaba A.i · Haïk S.a–e · Alpérovitch A.f, g
aAP-HP, Cellule Nationale de Référence des Maladies de Creutzfeldt-Jakob, Groupe Hospitalier Pitié-Salpêtrière, bINSERM, UMR-S 975, Equipe Maladie d’Alzheimer – Maladies à prions, cCNRS, UMR 7225, dUniversité Pierre et Marie Curie Paris 06, UMR 7225, S-975, Centre de Recherche de l’Institut Cerveau-Moelle (CRICM), eCNR des ATNC, fINSERM, U708, Neuroépidémiologie, gUPMC Université Paris 06, UMR S708, Paris, hInstitut de Veille Sanitaire, Saint-Maurice, et iINSERM-CépiDc, Le Vésinet, France Neuroepidemiology 2011;37:188–192 (DOI:10.1159/000332764)
Background: Surveillance of Creutzfeldt-Jakob disease (CJD) is still an important issue because of the variant CJD epidemic, which is in decline and also because of the emergence of novel forms of animal transmissible spongiform encephalopathy with zoonotic potential and the risk of nosocomial and blood transfusion-related transmission. Active surveillance has been implemented in most European countries and requires important human resources and funding. Here, we studied whether national mortality and morbidity statistics can be used as reliable indicators. Methods: CJD data collected by the French national CJD surveillance centre were compared with data registered in the national mortality statistics. Results: From 2000 to 2008, the two sources reported fairly similar numbers of CJD deaths. However, analysis of individual data showed important between-sources disagreement. Nearly 24% of CJD reported by the mortality register were false-positive diagnoses and 21.6% of the CJD cases diagnosed by the surveillance centre were not registered as CJD in the national mortality statistics. One out of 22 variant CJD cases was not reported as having any type of CJD in the mortality statistics. Conclusions:These findings raise doubt about the possibility of a reliable CJD surveillance only based on mortality data.
|Direct payment||This item at the regular price: USD 38.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50